Cardiovascular Treatment Market (2025 - 2033)

Cardiovascular Treatment Market Summary

The global cardiovascular treatment market size was estimated at USD 241.18 billion in 2024 and is projected to reach USD 383.11 billion by 2033, growing at a CAGR of 5.1% from 2025 to 2033. This market growth is driven by the rising prevalence of cardiovascular diseases (CVDs) such as coronary artery disease, stroke, heart failure, and hypertension, fueled by sedentary lifestyles, poor dietary habits, obesity, and an aging global population.

Increasing awareness of heart health and early diagnosis, coupled with advancements in diagnostic imaging, interventional cardiology, and minimally invasive surgical techniques, accelerating treatment adoption. Moreover, technological innovations such as drug-eluting stents, bioresorbable vascular scaffolds, and novel anticoagulant therapies are enhancing patient outcomes and expanding clinical applications.

Rising Prevalence of Cardiovascular Diseases (CVDs)

The rising prevalence of CVDs serves as a primary factor driving the global cardiovascular treatment market. As conditions such as hypertension, coronary artery disease, heart failure, and arrhythmias become increasingly common worldwide, the demand for effective therapeutic interventions continues to surge. Factors such as sedentary lifestyles, poor dietary habits, obesity, and diabetes, combined with an ageing global population, are intensifying the incidence of these chronic heart conditions.

In January 2024, the American Heart Association (AHA) reported that cardiovascular disease (CVD) was the leading cause of death in the U.S., claiming 931,578 lives, surpassing deaths from all cancers and chronic respiratory diseases combined. Therefore, cardiovascular devices are crucial in accurately detecting and mitigating heart disorders, fueling market expansion. The main drivers of this market include rapid technical development, an increase in affordable and effective devices, and rising demand for minimally invasive procedures.

The surge in the number of cases of chronic cardiovascular disorders contributes to the market growth. Increasing cardiovascular disorders have led to an increased demand for cardiovascular devices. Heart or coronary artery stents are among the most essential cardiovascular devices. They facilitate the treatment of cardiac illnesses considered a serious risk to life, namely heart attacks, coronary disease, atrial fibrillation, and the expansion of clogged arteries. In May 2024, the WHO reported that cardiovascular diseases (CVDs) are the top cause of disability and premature death in Europe, accounting for over 42.5% of annual deaths, around 10,000 daily. Men are nearly 2.5 times more likely to die from CVDs than women, with young people (ages 30-69) in Eastern Europe and Central Asia facing a nearly fivefold higher risk compared to their Western European counterparts.

Advancements in Technology, Diagnostics & Treatment Modalities:

Advancements in technology, diagnostics, and treatment modalities are major forces driving the cardiovascular treatment market. The development of next-generation biologics and fixed-dose combination drugs, such as PCSK9 inhibitors (for instance, Repatha by Amgen and Praluent by Sanofi) and SGLT2 inhibitors (for instance, Farxiga by AstraZeneca), has improved lipid and heart failure management, offering superior efficacy and adherence compared to traditional therapies (HTF MI). In the device and diagnostics segment, minimally invasive interventions such as transcatheter aortic valve replacement (TAVR) and drug-eluting stents (DES) have revolutionized cardiac surgery, reducing recovery time and procedural risks. Furthermore, the integration of digital health technologies and wearables, such as Apple Watch ECG features, Fitbit’s irregular heart rhythm notifications, and Abbott’s HeartMate 3 LVAD system with remote monitoring, enables continuous heart health tracking and early diagnosis of arrhythmias and other cardiac abnormalities.

In addition, AI-enabled imaging platforms, such as GE HealthCare’s CardioGraphe CT scanner and Siemens Healthineers’ AI-Rad Companion, have enhanced the precision of cardiovascular diagnostics, facilitating faster and more accurate detection of heart diseases. These innovations support a shift toward proactive, preventive care, where early detection and remote monitoring reduce the burden of acute cardiovascular events. Collectively, technological advancements in pharmaceuticals, devices, and digital diagnostics are enhancing treatment outcomes, expanding patient access, and driving robust growth in the global cardiovascular treatment market.

Launch of GRACE Project: Transforming Cardiovascular Care through Innovation and Collaboration

The GRACE Project, launched in March 2025 by UMC Utrecht and 23 international partners, represents a major innovation trend in cardiovascular care. Funded under the EU’s Horizon Europe Innovative Health Initiative (IHI) with a budget of USD 22.16 million, the project aims to modernize cardiovascular treatment through digital health integration, predictive analytics, and collaborative research.

Innovation Trend & How It Drives the Market

• Digital health + AI/analytics: The GRACE project explicitly uses digital health technologies and predictive analytics to shift cardiovascular care from reactive to proactive. For instance, remote monitoring of AF, digital follow-up in AS, and predictive models in HF all use data & technology.

  • This aligns with the broader trend: using wearables, remote monitoring, AI-based diagnostics and real-time capture of health data is opening new treatment and care models.

  • As these technologies become validated and integrated into care pathways, they expand the market for cardiovascular treatments (devices, digital services, software, follow-up care) beyond just drugs and surgery.

• Early detection & prevention: One of the pilot studies is specifically aimed at early detection of AF and remote monitoring post-ablation. By catching cardiac rhythm disorders before major events, GRACE supports the shift to prevention and early intervention.

  • This means more patients enter the treatment pathway earlier, increasing the size of the addressable market (diagnostics + monitoring + early therapy) rather than only late-stage treatment.

  • Early detection also tends to reduce acute events (which are expensive and resource-intensive) and may shift spending toward ongoing monitoring and management-opening new segments.

• Holistic and personalized care pathways: GRACE’s “holistic pathway” pilot brings together prevention, diagnosis, and management for multiple conditions (AF, HF, CAD) using personalized strategies and patient empowerment.

  • This reflects the trend where cardiovascular care is not just about fixing a blocked artery or replacing a valve, but about long-term management with patient engagement, digital tools, lifestyle, post-procedural follow-up.

  • This holistic model creates demand for integrated solutions (monitoring devices + software + tele-medicine + patient apps + follow-up services) and thus expands the market beyond traditional therapy.

• Collaboration and real-world validation: With 24 partners across industry, academia, hospitals and different countries and multiple pilot sites, GRACE emphasizes collaboration and scalability in real-world healthcare systems.

  • Real-world pilots increase the chance of adoption, reimbursement and scaling of innovations, which in turn drives market growth.

  • When an innovation is validated across health systems and countries, it becomes more likely to be commercialized and adopted widely thus enabling the growth of the underlying market.

The project is reforming the cardiovascular treatment market by integrating diagnostics, digital monitoring, and therapeutic interventions into a unified care model. This convergence of devices and software expands the definition of cardiovascular “treatment” beyond traditional drugs and procedures. It also drives a shift from episodic, procedure-based care to continuous, monitoring-based management, encouraging new reimbursement and delivery models. Moreover, GRACE signals growing health system readiness to adopt digital and AI-driven cardiovascular solutions, creating fresh opportunities for companies in diagnostics, wearables, remote monitoring, and patient engagement technologies.

Increased Awareness, Screening and Preventive Measures

Public health programs and educational campaigns have significantly improved understanding of cardiovascular risk factors such as hypertension, high cholesterol, obesity, and diabetes, prompting individuals to undergo regular screenings and seek timely medical intervention. This early identification of at-risk patients expands the patient pool requiring ongoing management and preventive therapy. In September 2025, The Jayadeva Institute of Cardiovascular Sciences and Research launched a public awareness campaign aimed at addressing the alarming rise in heart attack cases among young individuals. The initiative focuses on educating people about early warning signs, risk factors, and lifestyle habits that contribute to cardiac issues, such as stress, poor diet, smoking, lack of exercise, and excessive screen time. Through community outreach programs, social media engagement, and educational workshops, the campaign seeks to promote preventive health practices, encourage regular cardiac check-ups, and dispel the myth that heart diseases only affect older adults.

The Premature Coronary Artery Disease (PCAD) project at Jayadeva said:

“Lifestyle habits such as smoking, tobacco use, excessive alcohol consumption, sedentary routines, unhealthy diets high in fats and carbohydrates, and sugary beverages are major contributors. Rising obesity, diabetes, hypertension, high cholesterol, stress, pollution, and family history further aggravate the risk,”

Moreover, the widespread use of preventive medications such as lipid-lowering agents, antihypertensives, and antiplatelet drugs has shifted healthcare strategies from reactive treatment of acute cardiac events to long-term prevention of disease progression. As a result, pharmaceutical companies, diagnostic providers, and healthcare facilities benefit from sustained demand for cardiovascular products and services, fueling overall market growth.

Shift Toward Minimally Invasive and Connected Care

The growing shift toward minimally invasive and connected care is significantly driving the market by transforming how cardiac conditions are diagnosed, treated, and managed. Minimally invasive cardiac procedures such as transcatheter aortic valve replacement (TAVR), coronary stenting, and catheter-based ablations offer faster recovery, lower complication rates, and reduced hospital stays compared to traditional open-heart surgeries. These clinical and economic advantages have increased patient and physician preference for such approaches, accelerating the adoption of advanced cardiovascular devices.

At the same time, the integration of digital health technologies, including remote patient monitoring systems, wearable cardiac trackers, and data-driven diagnostic platforms, enables continuous monitoring of heart function and early detection of abnormalities. This connected care ecosystem enhances treatment adherence, facilitates personalized therapy adjustments, and reduces hospital readmissions.

Below is the Table Summarizing Key Developments and Innovations in the Market:

Source: Secondary Research, Grand View Research

Market Characteristics & Concentration

The chart below represents the relationship between industry concentration, industry characteristics, and industry participants. The industry is fragmented, with many large and small service providers in the market. There is a high degree of innovation, moderate level of merger & acquisition activities, high impact of regulations, and high expansion of industry.

The industry is experiencing a high degree of innovation. In September 2025, Relief Cardiovascular announced the first-in-human procedures with its world’s first transcatheter smart implant marks a major milestone in the treatment of congestion associated with heart failure. This breakthrough device combines advanced, minimally invasive transcatheter technology with real-time monitoring and intelligent control capabilities, aiming to actively manage fluid buildup and hemodynamic pressure in patients with heart failure.

Chief Executive Officer of Relief Cardiovascular said:

"Achieving first-in-human use is a major milestone for Relief Cardiovascular and a testament to the strength of our clinical and engineering teams," "Seeing the immediate, tunable hemodynamic effect in our treated patients strengthens our conviction that data-driven therapeutic implants represent the future of heart failure treatment. These procedures mark the beginning of that future."

Several key players are actively engaging in partnerships & collaborations to promote growth & innovation and improve their competitiveness by combining the expertise & efforts of different organizations. For instance, in September 2025, Novartis’ acquired Tourmaline Bio marks a strategic move to strengthen its cardiovascular treatment portfolio, particularly in addressing atherosclerotic cardiovascular disease (ASCVD), one of the world’s leading causes of morbidity and mortality. The deal brings into Novartis’ pipeline pacibekitug, an anti-inflammatory therapeutic candidate that targets the interleukin-6 (IL-6) pathway, a key driver of vascular inflammation associated with ASCVD. By integrating pacibekitug, Novartis aims to expand its late-stage cardiovascular assets and complement existing therapies focused on lipid lowering and heart failure management.

The market is regulated by a variety of guidelines designed to ensure patient safety, quality of care, and ethical business practices. In August 2025, The European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) issued a Focused Update (2025) to the 2019 guidelines on dyslipidaemias (lipid management), introducing a new approach to assessing cardiovascular risk and achieving lipid-treatment goals. This guidance shifts the paradigm from “wait and treat” based purely on lipid levels towards a more risk-based, individualized, proactive approach: use advanced, age-appropriate risk calculators to identify who will benefit most, initiate timely therapy (often combination) to meet LDL-cholesterol goals, and tailor treatment even for groups traditionally considered low or moderate risk but with unique risk modifiers.

In November 2025, Medanta inaugurated a dedicated Advanced Surgical Heart Failure Clinic, aimed at supporting patients with complex and end-stage heart failure. This clinic brings together multidisciplinary expertise cardiac surgeons, heart-failure specialists, interventional cardiologists, and rehabilitation teams under one roof to offer integrated care for very sick patients.

Chairman & Managing Director, Medanta, said:

“Heart failure represents one of the most pressing challenges in modern medicine. For patients with end-stage or complex heart failure, conventional medical management alone is often not enough. Our Advanced Surgical Heart Failure Clinic is designed to bridge this gap, offering advanced surgical solutions and a chance for a better quality of life.”

Treatment Type Insights

Interventional procedures segment held a significant share of 57.55% in 2024 and is expected to grow to the fastest CAGR during the forecast period. This growth is primarily driven due to the rising prevalence of CVDs such as coronary artery disease, stroke, and peripheral artery disease, fueled by aging populations, sedentary lifestyles, and increasing incidences of obesity, diabetes, and hypertension. Advancements in minimally invasive technologies, including drug-eluting stents, bioresorbable scaffolds, and transcatheter heart valve replacement systems, are further enhancing procedural safety and outcomes, leading to wider adoption among healthcare providers. For instance, in October 2025, Terumo India announced the launch of the FineCross M3 Coronary Micro‑Guide Catheter in India, marking a significant expansion of its interventional cardiology portfolio. With this launch the company aims to strengthens its role in India’s growing interventional cardiology market and expands its offering of advanced tools to help manage increasingly complex coronary cases.

The non‑invasive procedures segment is expected to grow at a significant CAGR during the forecast period. This growth is attributed to the increasing preference for safer, less traumatic treatment options. Patients and healthcare providers are shifting toward non-invasive diagnostic and therapeutic techniques such as cardiac imaging, CT angiography, and transcatheter interventions due to their reduced risk of complications, shorter hospital stays, and faster recovery times compared to traditional open-heart surgeries. Technological advancements, including the development of high-precision imaging systems, robotics, and AI-assisted diagnostic tools, are further enhancing the accuracy and outcomes of non-invasive cardiovascular procedures.

Indication Insights

Ischemic heart disease (IHD) segment held the largest share of 47.91% in 2024. This growth is primarily driven due to the rising global prevalence of lifestyle-related risk factors such as obesity, hypertension, diabetes, smoking, and sedentary behavior, which significantly increase the incidence of coronary artery blockages. Aging populations, especially in developed and emerging economies, further contribute to a growing patient pool requiring long-term management and interventional procedures. Advancements in diagnostic imaging, minimally invasive surgeries, and drug-eluting stents have improved patient outcomes, encouraging higher adoption of modern treatment modalities.

The heart failure & cardiomyopathies segment is expected to grow at the fastest CAGR during the forecast period. This growth is attributed to the increasing global prevalence of cardiovascular diseases, fueled by aging populations, sedentary lifestyles, obesity, and rising incidences of hypertension and diabetes. Advancements in diagnostic imaging and biomarker technologies have improved early detection and patient management, supporting market expansion. In addition, the growing adoption of innovative therapies such as gene therapy, stem cell therapy, and left ventricular assist devices (LVADs) is enhancing treatment outcomes and driving clinical interest. Pharmaceutical innovation, including novel drug classes such as angiotensin receptor-neprilysin inhibitors (ARNIs) and SGLT2 inhibitors, has further broadened treatment options.

Care Setting Insights

Hospitals segment held a significant share of 63.26% in 2024. This growth is primarily driven due to their advanced infrastructure, specialized care capabilities, and increasing patient inflow for complex cardiac procedures. Hospitals benefit from access to cutting-edge technologies, including cardiac imaging systems, minimally invasive surgical equipment, and robotic-assisted surgery platforms, which enhance patient outcomes and operational efficiency. Moreover, the growing availability of skilled cardiologists and multidisciplinary cardiac care units support comprehensive treatment and post-operative care.

The outpatient facilities segment is expected to grow at the fastest CAGR during the forecast period. This growth is attributed to the increasing preference for minimally invasive procedures, and advancements in diagnostic and interventional technologies. Outpatient settings such as ambulatory surgical centers and specialized cardiac clinics offer cost-effective, efficient, and patient-friendly alternatives to inpatient hospital stays, reducing both recovery time and healthcare expenditure. Moreover, growing emphasis on preventive cardiology, coupled with improved access to advanced imaging modalities such as echocardiography and cardiac CT scans in outpatient environments, further accelerates market growth.

Regional Insights

North America cardiovascular treatment market dominated the market and accounted for the largest revenue share of 35.95% in 2024, driven by the rising incidence of Atrial Fibrillation (AFib) & CVD, supportive government initiatives, and technological advancements. In February 2024, an article in The Lancet Regional Health - Europe discussed that atrial fibrillation (AF) is quite common, with an estimated lifetime risk of approximately 1 in 3 to 5 people over the age of 45. AFib results in significant hospitalizations and deaths each year, emphasizing the urgent need for advanced cardiovascular devices.

U.S. Cardiovascular Treatment Market Trends

The U.S. market is experiencing significant growth, driven by the rising CVD cases in the U.S. fuel the growth of the market. According to an American Heart Association (AHA) article published in January 2024, CVD results in about 2,552 deaths each day in the U.S. This significant burden of CVD on public health increased the critical need for effective management and treatment options within the U.S. market. In October 2023, Abbott launched the Abbott HeartMates program to support heart patients by enabling participants to share their stories and connect with people going through similar heart health conditions. Under this program, the company started the campaign with Damar Hamlin, a professional football player, as its first ambassador.

Asia Pacific Cardiovascular Treatment Market Trends

Asia Pacific is expected to grow at the fastest CAGR over the forecast period. The rising elderly population in the Asia Pacific contributes to market growth. In May 2024, the Asian Development Bank (ADB) indicated that by 2050, nearly 1.2 billion people aged 60 and older is expected to live in developing Asia and the Pacific, representing about a quarter of the overall population.

Cardiovascular treatment market in Chinaheld a significant revenue share in 2024. The increasing demand for advanced medical devices in China boosts demand for cardiovascular devices. In April 2024, Arineta revealed its collaboration with Shandong Yituo Medical Technology Development Co., Ltd. (SYMT). They are establishing a joint venture called Arineta (Shandong) Medical Equipment Co. Ltd., which is likely to install its inaugural SpotLight Duo at a prominent healthcare facility in Jinan, China, to meet the increasing demand for high-quality cardiac CT services in the region.

Europe Cardiovascular Treatment Market Trends

The market in Europe is expected to witness high growth due to the high mortality of CVDs in the region. According to a WHO article published in May 2024, CVDs are the leading cause of disability and premature death in Europe. It is responsible for over 42.5% of all deaths annually, accounting for approximately 10,000 deaths every day. The significant impact of CVD emphasizes the urgent need for advanced cardiovascular device solutions.

Germany cardiovascular treatment marketheld a significant revenue share in 2024. The rising number of cardiac surgery patients fuels market growth. Effective monitoring is crucial for ensuring patient safety, optimizing surgical outcomes, and managing postoperative recovery. In January 2024, The Journal of Thoracic and Cardiovascular Surgery reported data from a German registry for 2023, detailing 168,841 cardiac and vascular procedures across 77 hospitals. The unadjusted in-hospital survival rates were 97.6% for 28,996 coronary artery bypass grafts, 97.7% for 39,859 heart valve procedures, and 99.2% for 19,699 pacemaker/ICD implants. In addition, 2,982 extracorporeal life support procedures and 324 heart transplants were performed.

Latin America Cardiovascular Treatment Market Trends

The Latin America market is witnessing a significant trend. The market is growing due to the rising incidence of CVD disorders and technological advancements. A February 2024 review in the International Journal of Cardiovascular Sciences highlighted that cardiovascular risk factors are common among women in Los Angeles. Factors such as PCOS, early menopause, and gestational diabetes, along with autoimmune diseases such as lupus and rheumatoid arthritis, significantly increase these risks for women compared to men.

The cardiovascular treatment in Brazilheld the significant market share in 2024. Rising healthcare expenditures and government initiatives aim to improve cardiac care infrastructure. For instance, in September 2024, Claritas launched its Brazilian subsidiary, Claritas NucMed Tech Brazil, to commercialize software solutions for nuclear medicine. The focus was on positron emission tomography (PET) and single photon emission computed tomography (SPECT) software suites. These products aimed to tackle challenges such as high costs and access issues in Brazil. The registration process with ANVISA, Brazil’s medical device regulator, was underway at that time.

Middle East & Africa Cardiovascular Treatment Market Trends

The market in MEA is anticipated to grow significantly as the region is witnessing a rise in the prevalence of CVDs, including cardiac arrhythmias, such as AFib and VT. A sedentary lifestyle, unhealthy diets, and an aging population contribute to the increasing burden of CVDs, driving the demand for cardiovascular devices for diagnosis & treatment in the region. Several countries in the MEA are increasing their healthcare expenditure to improve healthcare access and quality.

Cardiovascular treatment market Saudi Arabia is driven by the growing prevalence of CVD cases drives the growth of the market. According to the article published by BMC Cardiovascular Diseases in March 2024, the prevalence of CVD among individuals aged 15 years and older in Saudi Arabia is 1.6%. This figure represents the percentage of the population within this age group affected by various cardiovascular conditions, including heart disease and related disorders. The data emphasizes a significant aspect of the country's health profile, providing insights into the extent of cardiovascular issues impacting Saudi Arabia's population.

Key Cardiovascular Treatment Company Insights

The market is fragmented, with the presence of many cardiovascular treatment providers.The market players undertake several strategic initiatives, such as partnerships & collaborations, product launches, mergers & acquisitions, and geographical expansion to maintain their position and grow in the market.

Recent Developments

• In November 2025, Merck Foundation launched a significant five-year initiative the Collaborative for Equity in Cardiac Care committing USD 22 million to improve access to high-quality, person-centered cardiovascular care in the U.S. Under this initiative, the Foundation is providing grants to 11 nonprofit and public health organizations in underserved communities across the country, supporting the development and implementation of evidence-informed programs to address gaps in cardiac care delivery.

“Cardiovascular disease continues to be the number one cause of death for men and women living in the U.S., and its burden hits under-resourced communities the hardest. By addressing the medical and social needs of people living with heart conditions, the Collaborative for Equity in Cardiac Care will have a significant, lasting impact on the health and wellbeing of individuals and communities across the country,” said, vice president and head, Social Impact & Sustainability, Merck.

• In June 2025, Recordati S.p.A. signed a strategic licensing and distribution agreement with Amarin Corporation to market the cardiovascular drug Vazkepa (icosapent ethyl) across 59 countries, with a primary focus on Europe. The collaboration aims to expand access to this advanced lipid management therapy, which is clinically proven to reduce cardiovascular risk in patients with elevated triglyceride levels despite statin therapy.

"By acquiring Cimar, DeepHealth is taking a powerful step in redefining imaging-based care through a portfolio of solutions that connect clinical and operational intelligence to enable faster, more accurate diagnoses and improve efficiency," CEO and president of RadNet’s Digital Health division, DeepHealth, said in a statement.

• In October 2024, AstraZeneca strengthened its cardiovascular-treatment pipeline by signing an exclusive licensing agreement with CSPC Pharmaceutical Group Ltd to develop a novel, pre-clinical small molecule that targets Lipoprotein(a) named YS2302018. The therapy is intended to be developed either alone or in combination with AstraZeneca’s existing investigational oral PCSK9 inhibitor (AZD0780) for the management of dyslipidaemia and other cardiovascular indications.

Cardiovascular Treatment Market